A new oral diabetes medication called orforglipron demonstrated superior blood sugar control compared to semaglutide in a multinational phase 3 clinical trial published in The Lancet. The study, known as ACHIEVE-3, tested orforglipron in adults with type 2 diabetes inadequately controlled with metformin over 52 weeks.
Orforglipron belongs to the GLP-1 receptor agonist class, the same category as popular diabetes and weight-loss drugs like semaglutide (Ozempic/Wegovy). The trial represents a significant development in diabetes treatment options, potentially offering patients an alternative oral medication with enhanced efficacy.